{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:42:52Z","timestamp":1793968972080,"version":"4.8.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA217169"],"award-info":[{"award-number":["R01CA217169"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA240472"],"award-info":[{"award-number":["R01CA240472"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","annalsthoracicsurgery.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Annals of Thoracic Surgery"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.athoracsur.2024.01.024","type":"journal-article","created":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T16:00:10Z","timestamp":1706976010000},"page":"119-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer"],"prefix":"10.1016","volume":"118","author":[{"given":"Elizabeth G.","family":"Dunne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cameron N.","family":"Fick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Isbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie E.","family":"Chaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Altorki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Spicer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puneeth","family":"Iyengar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"David H.","family":"Harpole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas E.","family":"Stinchcombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moishe","family":"Liberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Bott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasad S.","family":"Adusumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.athoracsur.2024.01.024_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib3","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib4","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the lace collaborative group","volume":"26","author":"Pignon","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib5","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jama.2019.11058","article-title":"Systemic therapy for locally advanced and metastatic non-small cell lung cancer: a review","volume":"322","author":"Arbour","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1158\/1078-0432.CCR-22-2994","article-title":"Five-year clinical outcomes after neoadjuvant nivolumab in resectable non-small cell lung cancer","volume":"29","author":"Rosner","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib7","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib8","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.lungcan.2019.05.029","article-title":"Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis","volume":"134","author":"Dafni","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib11","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib12","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","article-title":"Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial","volume":"29","author":"Cascone","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib13","article-title":"Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer","volume":"8","author":"Reuss","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib14","unstructured":"Feldman H, Sepesi B, Lin HY, et\u00a0al. Surgical outcomes after neoadjuvant chemotherapy plus nivolumab with and without ipilimumab in patients with non-small cell lung cancer. Presented at the 103rd Annual Meeting of the American Association for Thoracic Surgeons, Los Angeles, CA, May 6-9, 2023."},{"key":"10.1016\/j.athoracsur.2024.01.024_bib15","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial","volume":"22","author":"Altorki","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib16","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.21.00276","article-title":"Sakk 16\/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIa (N2) non-small-cell lung cancer\u2013a multicenter single-arm phase II trial","volume":"39","author":"Rothschild","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib17","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib18","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/OP.23.00014","article-title":"Perioperative therapy for resectable non-small-cell lung cancer: weighing options for the present and future","volume":"19","author":"Uprety","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib21","doi-asserted-by":"crossref","unstructured":"Spicer J, Gao S, Liberman M, Kato T, Tsuboi M, Lee S. Overall survival in the KEYNOTE-671 study for perioperative pembrolizumab for early-stage non-small cell lung cancer (NSCLC). Presented at the European Society for Medical Oncology (ESMO) Congress 2023, Madrid, Spain, October 20-24,\u00a02023.","DOI":"10.1016\/j.annonc.2023.10.052"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJMc2313778","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"390","author":"Heymach","year":"2024","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib23","unstructured":"Zhang LW, Zhang P, Wang W, et\u00a0al. Perioperative toripalimab\u00a0+ platinum-doublet chemotherapy vs chemotherapy in resectable stage II\/III non-small cell lung cancer (NSCLC): interim event-free survival (EFS) analysis of the phase III NEOTORCH study. Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 2-6,\u00a02023."},{"key":"10.1016\/j.athoracsur.2024.01.024_bib24","doi-asserted-by":"crossref","unstructured":"Cascone T, Awad MM, Spicer J, Lu S, Sepesi B, Tanaka F. Checkmate 77t: phase III study comparing neoadjuvant nivolumab (nivo) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant nivo or placebo for previously untreated, resectable stage II-IIIb NSCLC. Presented at the European Society for Medical Oncology (ESMO) Congress 2023, Madrid, Spain, October 20-24,\u00a02023.","DOI":"10.1016\/j.annonc.2023.10.050"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib25","first-page":"5614","article-title":"Neoadjuvant and adjuvant immunotherapy in early-stage non-small-cell lung cancer, past, present, and future","volume":"10","author":"Szeto","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib26","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage Ib-IIIa non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.lungcan.2019.06.012","article-title":"Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: the global, multicenter express study","volume":"134","author":"Dietel","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","article-title":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIa non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial","volume":"34","author":"Felip","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib29","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(22)00518-6","article-title":"Pembrolizumab versus placebo as adjuvant therapy for completely resected stage Ib-IIIa non-small-cell lung cancer (PEARLS\/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial","volume":"23","author":"O\u2019Brien","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib30","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jtho.2021.03.017","article-title":"Predictors of response, progression-free survival, and overall survival in patients with lung cancer treated with immune checkpoint inhibitors","volume":"16","author":"Memmott","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib31","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1007\/s12325-021-01675-0","article-title":"Curative-intent treatment with durvalumab in early-stage cancers","volume":"38","author":"Melillo","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib32","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib33","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41571-021-00501-4","article-title":"Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer","volume":"18","author":"Chaft","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib35","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.jtho.2020.05.020","article-title":"Neoadjuvant immunotherapy for NSCLC: current concepts and future approaches","volume":"15","author":"Uprety","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib36","doi-asserted-by":"crossref","unstructured":"Spicer J, Forde PM, Provenicio M, et\u00a0al. Clinical outcomes with neoadjuvant nivolumab\u00a0+ chemotherapy (C) vs C by definitive surgery in patients with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial. Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 2-6,\u00a02023.","DOI":"10.1200\/JCO.2023.41.16_suppl.8521"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib37","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.2009.27.6204","article-title":"Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer","volume":"28","author":"Felip","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib38","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2010.33.7089","article-title":"Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages Ib to IIIa non-small-cell lung cancer","volume":"30","author":"Scagliotti","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib39","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jtcvs.2022.01.019","article-title":"Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer","volume":"164","author":"Sepesi","year":"2022","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib40","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jtcvs.2023.01.034","article-title":"Turning the tides on the perioperative care of resectable lung cancer","volume":"166","author":"Seitlinger","year":"2023","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib41","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.3390\/ijms22126288","article-title":"Anti-PD1\/PD-L1 immunotherapy for non-small cell lung cancer with actionable oncogenic driver mutations","volume":"22","author":"Dantoing","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib43","unstructured":"Soloman BJ, Ahn JS, Dziadziusko R, Barlesi F, Hoffmann F, Nishio M. Alina: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC). Presented at the European Society for Medical Oncology (ESMO) Congress 2023, Madrid, Spain, October 20-24,\u00a02023."},{"key":"10.1016\/j.athoracsur.2024.01.024_bib44","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.21.02660","article-title":"Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIa non-small-cell lung cancer (NADIM phase II trial)","volume":"40","author":"Provencio","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2024.01.024_bib45","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","article-title":"Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA","volume":"616","author":"Abbosh","year":"2023","journal-title":"Nature"}],"container-title":["The Annals of Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497524000808?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003497524000808?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T20:38:57Z","timestamp":1719002337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003497524000808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0003497524000808"],"URL":"https:\/\/doi.org\/10.1016\/j.athoracsur.2024.01.024","relation":{},"ISSN":["0003-4975"],"issn-type":[{"value":"0003-4975","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Emerging Role of Immunotherapy in Resectable Non-Small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"The Annals of Thoracic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athoracsur.2024.01.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The Society of Thoracic Surgeons. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}